Sen. Warren calls for release of Trump-era pharma pricing contracts amid accusations against RFK Jr.

Sen. Warren has publicly demanded that the contracts governing drug pricing under the Trump administration be disclosed. She alleges that RFK Jr. is concealing these agreements, raising concerns about transparency in pharmaceutical pricing.

The Food and Drug Administration announced a new pilot program aimed at accelerating the timeline for drug developers to move candidates into clinical trials. The initiative seeks to streamline regulatory processes and reduce delays for promising therapies.

In the political arena, Democrats are preparing to launch health‑care investigations following the recent midterm elections. The probes are expected to examine a range of issues, including drug pricing practices and the influence of pharmaceutical companies on policy.